Join the #FierceMadness!
Pick your favorite drug names in this year's tournament challenge. Read more and vote here!
“Agreeing to refund the used doses of Dengvaxia would imply that the vaccine is ineffective, which is not the case,” said Sanofi.
AstraZeneca made deals with China's Alibaba and Tencent as the British drugmaker reported double-digit growth in the country.
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
Ready to challenge GlaxoSmithKline and Merck, India's Bharat Biotech has won WHO prequalification for its rotavirus vaccine Rotavac.
Mylan and Biocon have won an EU recommendation for their Lantus biosimilar after overcoming manufacturing concerns that forced a delay last summer.
U.S biotech Evolus alerted investors that FDA concerns with a Daewoong plant in South Korea that will make its Botox copy could delay its approval.
A Sanofi executive said the company will "shoulder the cost" of any adverse events that are scientifically linked to vaccination.
As investigations in the Philippines proceed, Sanofi Pasteur has agreed to refund the cost of unused Dengvaxia doses worth about $28 million.
BMS’s Opdivo is the only immuno-oncology drug approved to treat kidney cancer, but more rivals are threatening that status.
Following mass immunization program halt, Dengvaxia’s marketing authorization in the Philippines has been put on hold for a year.
Chinese pharmaceutical database PharmCube highlighted 16 possible blockbuster approvals in China in 2018.